GLAXOSMITHKLINE LLC FDA Approval NDA 016042

NDA 016042

GLAXOSMITHKLINE LLC

FDA Drug Application

Application #016042

Documents

Letter2007-05-29
Letter2010-02-26
Letter2011-03-17
Label2010-03-03
Label2011-03-21
Letter2020-08-21
Label2020-08-27

Application Sponsors

NDA 016042GLAXOSMITHKLINE LLC

Marketing Status

Discontinued002
Prescription003

Application Products

002CAPSULE;ORAL25MG;50MG0DYAZIDEHYDROCHLOROTHIAZIDE; TRIAMTERENE
003CAPSULE;ORAL25MG;37.5MG1DYAZIDEHYDROCHLOROTHIAZIDE; TRIAMTERENE

FDA Submissions

TYPE 4; Type 4 - New CombinationORIG1AP1965-12-02STANDARD
REMS; REMSSUPPL8AP1976-06-23STANDARD
REMS; REMSSUPPL14AP1976-01-27STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL16AP1975-02-27STANDARD
LABELING; LabelingSUPPL17AP1975-02-27
LABELING; LabelingSUPPL18AP1976-06-23
LABELING; LabelingSUPPL19AP1975-06-12
MANUF (CMC); Manufacturing (CMC)SUPPL21AP1976-01-27STANDARD
LABELING; LabelingSUPPL23AP1976-05-21
LABELING; LabelingSUPPL24AP1976-05-21
LABELING; LabelingSUPPL25AP1976-11-03
LABELING; LabelingSUPPL26AP1977-04-12
MANUF (CMC); Manufacturing (CMC)SUPPL27AP1977-02-14STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL28AP1977-02-14STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL29AP1977-06-14STANDARD
LABELING; LabelingSUPPL30AP1978-02-22
LABELING; LabelingSUPPL31AP1978-02-22
LABELING; LabelingSUPPL32AP1978-02-22
LABELING; LabelingSUPPL33AP1978-02-22
MANUF (CMC); Manufacturing (CMC)SUPPL34AP1978-01-19STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL35AP1978-01-19STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL36AP1978-01-19STANDARD
LABELING; LabelingSUPPL37AP1979-09-18
LABELING; LabelingSUPPL38AP1979-09-18
LABELING; LabelingSUPPL39AP1979-09-18
MANUF (CMC); Manufacturing (CMC)SUPPL40AP1981-02-02STANDARD
LABELING; LabelingSUPPL41AP1979-12-06
LABELING; LabelingSUPPL43AP1980-01-14
LABELING; LabelingSUPPL44AP1981-01-27
LABELING; LabelingSUPPL45AP1980-07-14
LABELING; LabelingSUPPL46AP1982-02-23
LABELING; LabelingSUPPL47AP1988-04-26
LABELING; LabelingSUPPL48AP1981-10-30
LABELING; LabelingSUPPL49AP1982-08-25
LABELING; LabelingSUPPL51AP1982-10-08
LABELING; LabelingSUPPL52AP1985-01-03
MANUF (CMC); Manufacturing (CMC)SUPPL54AP1983-05-13STANDARD
EFFICACY; EfficacySUPPL55AP1994-03-03UNKNOWN
LABELING; LabelingSUPPL56AP1985-03-07
LABELING; LabelingSUPPL57AP1986-07-29
MANUF (CMC); Manufacturing (CMC)SUPPL59AP1988-02-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL61AP1991-12-02STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL62AP1992-05-01STANDARD
LABELING; LabelingSUPPL64AP1994-03-03STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL65AP1994-05-20STANDARD
LABELING; LabelingSUPPL66AP1994-12-01STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL67AP1998-08-31STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL68AP1999-03-16STANDARD
LABELING; LabelingSUPPL69AP2001-02-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL70AP2000-12-20STANDARD
LABELING; LabelingSUPPL74AP2007-05-18STANDARD
LABELING; LabelingSUPPL77AP2010-02-23UNKNOWN
LABELING; LabelingSUPPL78AP2011-03-15UNKNOWN
LABELING; LabelingSUPPL79AP2020-08-20STANDARD

Submissions Property Types

SUPPL8Null0
SUPPL14Null0
SUPPL16Null0
SUPPL21Null0
SUPPL27Null0
SUPPL28Null0
SUPPL29Null0
SUPPL34Null0
SUPPL35Null0
SUPPL36Null0
SUPPL40Null0
SUPPL54Null0
SUPPL59Null0
SUPPL61Null0
SUPPL62Null0
SUPPL65Null0
SUPPL67Null0
SUPPL68Null0
SUPPL70Null0
SUPPL77Null6
SUPPL78Null6
SUPPL79Null6

TE Codes

003PrescriptionAB

CDER Filings

GLAXOSMITHKLINE LLC
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 16042
            [companyName] => GLAXOSMITHKLINE LLC
            [docInserts] => ["",""]
            [products] => [{"drugName":"DYAZIDE","activeIngredients":"HYDROCHLOROTHIAZIDE; TRIAMTERENE","strength":"25MG;50MG","dosageForm":"CAPSULE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"DYAZIDE","activeIngredients":"HYDROCHLOROTHIAZIDE; TRIAMTERENE","strength":"25MG;37.5MG","dosageForm":"CAPSULE;ORAL","marketingStatus":"Prescription","te":"","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"08\/20\/2020","submission":"SUPPL-79","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/016042s079lbl.pdf\"}]","notes":""},{"actionDate":"03\/15\/2011","submission":"SUPPL-78","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2011\\\/016042s078lbl.pdf\"}]","notes":""},{"actionDate":"02\/23\/2010","submission":"SUPPL-77","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2010\\\/016042s077lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"DYAZIDE","submission":"HYDROCHLOROTHIAZIDE; TRIAMTERENE","actionType":"25MG;50MG","submissionClassification":"CAPSULE;ORAL","reviewPriority":"Discontinued","inserts":"[]","notes":">No"},{"actionDate":"DYAZIDE","submission":"HYDROCHLOROTHIAZIDE; TRIAMTERENE","actionType":"25MG;37.5MG","submissionClassification":"CAPSULE;ORAL","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"}]
            [supplements] => 
            [actionDate] => 2020-08-20
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.